Our global sites Open Search About us Our science Our products Investors Sustainability Careers Get in touch Analyst coverage Allergy Therapeutics PLC Shareholder services Analyst coverage Overview At a glance Financial highlights Investment case Regulatory news Email alert Results, reports and presentations Financial Calendar Share tools Shareholder services AGM information Registrar Details Major shareholders Analyst coverage Electronic communications AIM Rule 26 Corporate governance Investor and Advisor Contacts Research analysts have, from time to time, published material commenting on allergy therapeutics. Any opinions, estimates or forecasts regarding the Company's performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. You should, therefore, not place undue reliance on the content of any such analyst report or statement. The following analysts currently issue reports on us: Company Analyst Panmure Gordon Mike Mitchell FinnCap Limited Mark Brewer Numis Securities Paul Cuddon Trinity Delta Lala Gregorek These reports cannot be obtained directly from us. Click for top of the page Linkedin icon Quick links Head office General inquiries Terms and Conditions Privacy Statement Cookies Adverse Event Reporting Modern Slavery and Human Trafficking Statement Gender Pay Gap QCA Code Compliance statement Contact us Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom Tel +44 (0)1903 844 700 © Allergy Therapeutics 2021. By Emperor Cookie Control

Our global sites Open Search About us Our science Our products Investors Sustainability Careers Get in touch The Opportunity Allergy Therapeutics PLC The Opportunity Allergy Therapeutics is well placed to respond to the trends driving demand for immunotherapy To excel our patient centric approach it is essential we continuously examine and evaluate our macro and micro environment. Macro Trends: Increase in pollen allergy Rapid increase in food allergies Use of probiotics to address respiratory and food allergies Digitalisation and AI in medicine State-of-the-art biotechnology developments such as VLP could permit precise and targeted removal of allergy Micro Trends: Commitment to the regulatory landscape as European regulators increase their focus on ensuring medicines are registered and fit for purpose Medicinal Adherence & Convenience Click for top of the page Linkedin icon Quick links Head office General inquiries Terms and Conditions Privacy Statement Cookies Adverse Event Reporting Modern Slavery and Human Trafficking Statement Gender Pay Gap QCA Code Compliance statement Contact us Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom Tel +44 (0)1903 844 700 © Allergy Therapeutics 2021. By Emperor Cookie Control